Phaseline

Targets › NPR2

NPR2 (Atrial natriuretic peptide receptor 2): drug programs, companies and trials

2 programs from 2 companies in 10 trials: 8 Phase 2, 2 Phase 3; Other, Metabolic and endocrine; next expected readout Mar 2027.

Receptor for the C-type natriuretic peptide NPPC/CNP hormone. Has guanylate cyclase activity upon binding of its ligand. (UniProt, P20594)

Open in Phaseline: the race on NPR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BioMarin PharmaceuticalVosoritide
Atrial natriuretic peptide receptor B binding agent
NPR2Phase 3Hypochondroplasia; Achondroplasia; Noonan Syndrome; Idiopathic Short Stature …Mar 2027
Ascendis Pharma Growth DisordersNavepegritide
C-type natriuretic peptide (CNP) analog
NPR2Phase 2AchondroplasiaNov 2027

Conditions

Achondroplasia (5) Hypochondroplasia (2) Noonan Syndrome (1) Idiopathic Short Stature (1) Short Stature (1)

Modalities

protein or peptide (2)

Companies

BioMarin Pharmaceutical (1) Ascendis Pharma Growth Disorders (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.